RAS oncology & therapy最新文献

{"title":"The Basic Science of Oncology","authors":"D. Gandía","doi":"10.51520/2766-2586-2","DOIUrl":"https://doi.org/10.51520/2766-2586-2","url":null,"abstract":"","PeriodicalId":74640,"journal":{"name":"RAS oncology & therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49530076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Serum Tumor Markers Variation, Following The Radioactive Iodine Therapy in Patients with Differentiated Thyroid Cancer","authors":"Sorush Niknamian","doi":"10.53902/SOJPCN.2020.01.000503","DOIUrl":"https://doi.org/10.53902/SOJPCN.2020.01.000503","url":null,"abstract":"Introduction: Radioactive iodine is the effective therapy in thyroid cancer. The aim\u0000of this study is to evaluate the serum tumor markers in patients under the therapy\u0000with radioactive iodine 131.\u0000Material and Methods: 45 cases of female patients aged 16-60 years with thyroid\u0000cancer surgery referred to the nuclear medicine department of Nemazi hospital for\u0000(iodine treatment after surgery) were selected. The selection was on the basis of\u0000interviewing and information of patients is consent forms. Only patients with thyroid\u0000cancer and referred for the first time without any other diseases were chosen for this\u0000study. The selected patients were prescribed a dose of 150 m Ci of I-131. From each\u0000patient, 4 mL of chelated serum for serological studies on tumor markers and 2 mL\u0000of oxalated serum for spectrophotometry studies on cell death were used in three\u0000stages. The first stage before the iodine therapy, the second stage, after 48 hours, and\u0000the third stage, 30 days after radioiodine therapy were studied and the results were\u0000evaluated by the one-way repeated measures ANOVA test.\u0000Results: According to the results of dependent paired T-Test, AFP, in the periods\u0000before, 48 hours and 1 month after radioiodine therapy, respectively were 3.46 ± 1.21\u0000and 3.74 ± 1.37 and 3.76 ± 1.25 (p <0.0005). About CA 19-9 in the periods before,\u000048 hours and one month after radioiodine therapy, the results were 9.30 ± 6.32, 9.95\u0000± 6.92 (p = 0.040) and 11.26 ± 7.49 (p <0.0005) respectively. About CEA, the results\u0000were 1.60 ± 0.60, 1.47 ± 0.55 and 2.23 ± 0.69 (p <0.0005), respectively. In the case\u0000of tumor marker CA 15-3 results were 15.53 ± 6.48 and 1.60 ± 0.60 and 15.68 ± 6.52\u0000(p = 0.014), respectively and in the case of ALP, results were 124.22 ± 5 and 122.2 ±\u00006 and 116.7 ± 7 (p <0.0005), respectively.\u0000Conclusion: According to the same studies and the acquired results, it can be\u0000concluded that the tumor markers CEA and CA19-9 are more acceptable and\u0000sustainable for monitoring the malignancy and progressive disease in patients with\u0000thyroid cancer. The decreasing ALP is normal and transient. The increase of AFP and\u0000CA15-3 is not even statistically reliable. It is recommended that the period of iodine\u0000therapy and falsely elevated tumor markers can be informed to the doctor, during\u0000the gastrointestinal studies in patients with thyroid cancer, in order to prevent wrong\u0000decisions on the treatment process.","PeriodicalId":74640,"journal":{"name":"RAS oncology & therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46242955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}